Skip to main content
SpringerLink
Log in

Deferasirox improves outcomes at acceptable cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Porter JB, Bowden D, Ganser A, Domokos G, Gater A, Baladi J-F, Cappellini MD.Improved health-related quality of life in patients with hematological disorders receiving deferasirox (Exjade Rm). 50th Annual Meeting and Exposition of the American Society of Hematology: abstr. 1307, 6 Dec 2008. Available from: URL: http://www.hematology.org

  2. Bozkaya D, Migliaccio-Walle K, Baladi J-F.Impact of management of iron overload in patients with myelodsplastic syndromes. 50th Annual Meeting and Exposition of the American Society of Hematology: abstr. 1308, 6 Dec 2008. Available from: URL: http://www.hematology.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deferasirox improves outcomes at acceptable cost. Pharmacoecon. Outcomes News 572, 9 (2009). https://doi.org/10.2165/00151234-200905720-00018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905720-00018

Keywords

Search

Navigation